Lipigon Pharmaceuticals AB (LPGO) - Total Liabilities
Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has total liabilities worth Skr3.57 Million SEK (≈ $384.51K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lipigon Pharmaceuticals AB - Total Liabilities Trend (2017–2025)
This chart illustrates how Lipigon Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Lipigon Pharmaceuticals AB to evaluate short-term liquidity relative to the company's equity base.
Lipigon Pharmaceuticals AB Competitors by Total Liabilities
The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wishbone Gold Plc
LSE:WSBN
|
UK | GBX155.25K |
|
Marechale Capital Plc
LSE:MAC
|
UK | GBX123.20K |
|
Premier African Minerals Ltd
LSE:PREM
|
UK | GBX60.88 Million |
|
Livento Group Inc.
NASDAQ:NUGND
|
USA | $2.80 Million |
|
AYURCANN HOLDINGS CORP.
F:3ZQ0
|
Germany | €15.44 Million |
|
Delta Electronics (Thailand) Public Company Limited
F:DLS
|
Germany | €67.70 Billion |
|
Velocity Composites plc
LSE:VEL
|
UK | GBX5.16 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Lipigon Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LPGO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lipigon Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lipigon Pharmaceuticals AB (2017–2025)
The table below shows the annual total liabilities of Lipigon Pharmaceuticals AB from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr3.57 Million ≈ $384.51K |
-49.41% |
| 2024-12-31 | Skr7.06 Million ≈ $759.98K |
+36.91% |
| 2023-12-31 | Skr5.16 Million ≈ $555.08K |
-25.73% |
| 2022-12-31 | Skr6.95 Million ≈ $747.39K |
+7.41% |
| 2021-12-31 | Skr6.47 Million ≈ $695.84K |
+186.23% |
| 2020-12-31 | Skr2.26 Million ≈ $243.10K |
+117.00% |
| 2019-12-31 | Skr1.04 Million ≈ $112.03K |
-2.44% |
| 2018-12-31 | Skr1.07 Million ≈ $114.83K |
-99.83% |
| 2017-12-31 | Skr619.85 Million ≈ $66.71 Million |
-- |
About Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which… Read more